Read by QxMD icon Read

Clinical Genitourinary Cancer

Chiara Ciccarese, Roberto Iacovelli, Claudia Mosillo, Giampaolo Tortora
No abstract text is available yet for this article.
June 21, 2018: Clinical Genitourinary Cancer
Hang Xu, Ping Tan, Jianzhong Ai, Yu Huang, Tianhai Lin, Lu Yang, Qiang Wei
PURPOSE: To identify the impact of albumin-globulin ratio (AGR) on pathologic and survival outcomes in patients with upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). PATIENTS AND METHODS: We retrospectively reviewed medical records of 620 patients treated with RNU for UTUC at our institution. Logistic regression analysis was used to evaluate the relation between low AGR (<1.45) and adverse pathologic features. Kaplan-Meier curves were used to estimate recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) probabilities between 2 groups...
June 14, 2018: Clinical Genitourinary Cancer
Safak Ozturk, Mutlu Unver, Zafer Onen, Hakan Ozturk, Erkan Sahin, Ragıp Ortac, Ethem Murat Sozbilen
No abstract text is available yet for this article.
June 12, 2018: Clinical Genitourinary Cancer
Renate Pichler, Josef Fritz, Felizian Lackner, Susanne Sprung, Andrea Brunner, Wolfgang Horninger, Wolfgang Loidl, Andreas Pircher, Isabel Heidegger
INTRODUCTION: The use of cisplatin-based adjuvant chemotherapy (AC) after radical cystectomy (RC) is a highly controversial issue and has been infrequently used owing to the high rates of postoperative complications, cisplatin ineligibility, and lack of randomized trials. Checkpoint inhibitors such as nivolumab, pembrolizumab, or atezolizumab are currently being tested in phase III studies in the adjuvant setting owing to their more favorable safety profile compared with chemotherapy...
June 8, 2018: Clinical Genitourinary Cancer
Elio Mazzone, Felix Preisser, Sebastiano Nazzani, Zhe Tian, Marco Bandini, Giorgio Gandaglia, Nicola Fossati, Denis Soulières, Markus Graefen, Francesco Montorsi, Shahrokh F Shariat, Fred Saad, Alberto Briganti, Pierre I Karakiewicz
PURPOSE: To quantify the prognostic effect of the location of prostate cancer (PCa) metastases on cancer-specific mortality (CSM) and the rate of other-cause mortality (OCM) in contemporary newly diagnosed metastatic PCa (mPCa) patients. PATIENTS AND METHODS: Within the Surveillance Epidemiology and End Results database (2004-2014), we focused on newly diagnosed mPCa patients. Data were stratified according to the site of metastases and age group. Cumulative incidence smoothed plots were generated for CSM and OCM at 5 years after diagnosis, according to the competing-risks methods...
June 5, 2018: Clinical Genitourinary Cancer
Francesco Cantiello, Fabio Crocerossa, Giorgio Ivan Russo, Vincenzo Gangemi, Matteo Ferro, Mihai Dorin Vartolomei, Giuseppe Lucarelli, Maria Mirabelli, Chiara Scafuro, Giuseppe Ucciero, Ottavio De Cobelli, Giuseppe Morgia, Rocco Damiano, Giuseppe Lucio Cascini
PURPOSE: To evaluate the diagnostic performance of 64 Cu-PSMA-617 positron emission tomography (PET) with computed tomography (CT) for restaging prostate cancer after biochemical recurrence (BCR) and to compare it with 18 F-choline PET/CT in a per-patient analysis. PATIENTS AND METHODS: An observational study was performed of 43 patients with BCR after laparoscopic radical prostatectomy who underwent 64 Cu-PSMA-617 PET/CT and subsequently 18 F-choline PET/CT for restaging...
June 4, 2018: Clinical Genitourinary Cancer
Horatio R Thomas, Ming-Hui Chen, Anthony V D'Amico, Charles L Bennett, Michael W Kattan, Oliver Sartor, Karen Stein, Paul L Nguyen
BACKGROUND: Previous studies have reported conflicting results on the relationship between androgen deprivation therapy (ADT) and the risk of depression. We assessed whether ADT is associated with depression in a unique data set of men with recurrent prostate cancer. PATIENTS AND METHODS: We studied a cohort of 656 men in the prospective COMPARE (Comprehensive, Multicenter, Prostate Adenocarcinoma) registry who experienced biochemical recurrence after radiation therapy (RT) only, radical prostatectomy (RP) with or without RT, or ADT with RP or RT...
June 1, 2018: Clinical Genitourinary Cancer
Consuelo Buttigliero, Marcello Tucci, Francesca Vignani, Rosario F Di Stefano, Gianmarco Leone, Clizia Zichi, Daniele Pignataro, Gaetano Lacidogna, Pamela Guglielmini, Gianmauro Numico, Giorgio V Scagliotti, Massimo Di Maio
BACKGROUND: Neutropenia is a common side effect associated with docetaxel use. We retrospectively investigated the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel. PATIENTS AND METHODS: Metastatic castration-resistant prostate cancer patients treated with first-line docetaxel, with known neutrophils value 10 days after first administration, were included in this retrospective analysis...
June 1, 2018: Clinical Genitourinary Cancer
Ayman Soubra, Mehmet Gencturk, Jerry Froelich, Priya Balaji, Shilpa Gupta, Gautam Jha, Badrinath R Konety
PURPOSE: To determine the accuracy of 18 F-fluorodeoxyglucose with positron emission tomography and computed tomography (FDG-PET/CT) scans in assessing the response to neoadjuvant chemotherapy (NAC) in patients with bladder cancer scheduled to undergo radical cystectomy (RC). PATIENTS AND METHODS: All patients treated at our center for muscle-invasive bladder cancer (MIBC) were counseled and offered NAC before RC. FDG-PET/CT scans were performed before the initiation of chemotherapy and after completion of the regimen...
May 31, 2018: Clinical Genitourinary Cancer
Riccardo Schiavina, Lorenzo Bianchi, Federico Mineo Bianchi, Marco Borghesi, Cristian Vincenzo Pultrone, Hussam Dababneh, Paolo Castellucci, Francesco Ceci, Cristina Nanni, Caterina Gaudiano, Michelangelo Fiorentino, Angelo Porreca, Francesco Chessa, Andrea Minervini, Stefano Fanti, Eugenio Brunocilla
PURPOSE: To evaluate the accuracy of 11 C-choline positron emission tomography (PET)/computed tomography (CT) for nodal staging of prostate cancer (PCa) in different populations of high-risk patients. PATIENTS AND METHODS: We evaluated 262 individuals with intermediate- or high-risk PCa submitted to radical prostatectomy and extended pelvic lymph node dissection. Within men with high-risk disease, we identified a subgroup of individuals harboring very high-risk (VHR, n = 28) disease: clinical stage ≥ T2c and more than 5 cores with Gleason score 8-10; primary biopsy Gleason score of 5; 3 high-risk features; or prostate-specific antigen ≥ 30 ng/mL...
May 30, 2018: Clinical Genitourinary Cancer
Kay M Westenfelder, Beatrice Lentes, Julia Rackerseder, Nassir Navab, Jürgen E Gschwend, Matthias Eiber, Tobias Maurer
No abstract text is available yet for this article.
May 29, 2018: Clinical Genitourinary Cancer
Andrew W Hahn, Camryn Froerer, Sidney VanAlstine, Nityam Rathi, Erin B Bailey, David D Stenehjem, Neeraj Agarwal
BACKGROUND: Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome composition is predictive of response to immunotherapy and cytotoxic chemotherapy. We sought to investigate whether antibiotics targeting Bacteroides species affect progression-free survival (PFS) while receiving first-line VEGF-TKI therapy. PATIENTS AND METHODS: Using a retrospective cohort of intermediate- and poor-risk metastatic renal-cell carcinoma patients from the University of Utah, we categorized patients receiving first-line VEGF-TKIs by receipt of antibiotics (Bacteroides spp...
May 29, 2018: Clinical Genitourinary Cancer
Oula Knuutinen, Hanne Kuitunen, Seppo Alahuhta, Juha-Matti Isokangas, Eila Sonkajärvi, Taina Turpeenniemi-Hujanen, Outi Kuittinen
No abstract text is available yet for this article.
May 26, 2018: Clinical Genitourinary Cancer
Jad Chahoud, Miao Zhang, Louis L Pisters, Song-Chang Lin, Sue-Hwa Lin, Shi-Ming Tu
No abstract text is available yet for this article.
May 25, 2018: Clinical Genitourinary Cancer
Inkeun Park, Se Hoon Lee, Jae Lyun Lee
BACKGROUND: The optimal treatment option for non-clear-cell renal cell carcinoma (nccRCC) is not established. We conducted a multicenter phase II trial of axitinib for patients with advanced nccRCC who had failed prior treatment with temsirolimus. PATIENTS AND METHODS: Patients with histologically confirmed metastatic or recurrent nccRCC received 5 mg axitinib twice daily. Prior use of vascular endothelial growth factor pathway inhibitors was not allowed. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate, overall survival, and safety...
May 23, 2018: Clinical Genitourinary Cancer
Charles C Peyton, Mounsif Azizi, Juan Chipollini, Cesar Ercole, Mayer Fishman, Scott M Gilbert, Timothy Juwono, Jorge Lockhart, Michael Poch, Julio M Pow-Sang, Philippe E Spiess, Lucas Wiegand, Wade J Sexton
BACKGROUND: Primary urethral carcinoma (PUC) is rare, and standard treatment recommendations are lacking. We examined the variation in treatments and survival outcomes of female PUC at a single, tertiary referral cancer center. METHODS: Records of women with PUC referred to our multidisciplinary genitourinary oncology service between 2003 and 2017 were reviewed. Clinical, demographic, pathologic, primary and salvage therapy details, and overall (OS) and recurrence-free survival (RFS) were recorded...
May 18, 2018: Clinical Genitourinary Cancer
Bente Brokstad Herlofson, Gry Karina Kjølle, Kristine Løken Westgaard, Ayca M Løndalen, Øyvind S Bruland
No abstract text is available yet for this article.
May 16, 2018: Clinical Genitourinary Cancer
Judith Bosschieter, Anouk Hentschel, C Dilara Savci-Heijink, J Patrick van der Voorn, Lawrence Rozendaal, André N Vis, Bas W G van Rhijn, Birgit I Lissenberg-Witte, Elisabeth E Fransen van de Putte, R Jeroen A van Moorselaar, Jakko A Nieuwenhuijzen
BACKGROUND: Histologic grade is an important prognosticator in patients with non-muscle-invasive bladder cancer (NMIBC). Currently, 2 classifications for grade are widely used; the World Health Organization (WHO) 1973 and the WHO 2004. We compare inter-observer variability of both classifications and investigate which histologic criteria cause this variability. Furthermore, the prognostic value of both classifications was assessed. PATIENTS AND METHODS: Three pathologists reviewed 328 bladder tissue samples of 232 patients with NMIBC in a blinded manner...
May 11, 2018: Clinical Genitourinary Cancer
Roberto Iacovelli, Ugo De Giorgi, Luca Galli, Paolo Zucali, Franco Nolè, Roberto Sabbatini, Anna Paola Fraccon, Umberto Basso, Alessandra Mosca, Francesco Atzori, Daniele Santini, Gaetano Facchini, Giuseppe Fornarini, Felice Pasini, Cristina Masini, Francesco Massari, Sebastiano Buti, Teodoro Sava, Cosimo Sacco, Riccardo Ricotta, Isabella Sperduti, Giampaolo Tortora, Camillo Porta
BACKGROUND: The International mRCC (metastatic renal cell carcinoma) Database Consortium (IMDC) is the standard classification for mRCC. We aimed to evaluate the outcomes of a large cohort of patients with an intermediate or a poor prognosis treated with sunitinib using a different cutoff point for IMDC to improve the classification. PATIENTS AND METHODS: Patients with an intermediate or a poor prognosis according to the IMDC criteria and treated with sunitinib were included in the present study...
May 7, 2018: Clinical Genitourinary Cancer
Arnaldo Stanzione, Renato Cuocolo, Sirio Cocozza, Massimo Imbriaco
No abstract text is available yet for this article.
May 7, 2018: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"